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Abstract Stimulation of CD40 has been previously shown to
result in a release of ceramide in small sphingolipid-enriched
rafts in the cell membrane [Grassme¤ et al., J. Immunol. 168
(2002) 298^307]. Those rafts fused to larger signaling platforms
that served to cluster CD40. Here, we de¢ned molecular mech-
anisms of CD40 clustering in membrane platforms. To this end,
we replaced the transmembranous domain of CD40 with that of
CD45, a molecule known to be excluded from lipid rafts. Mu-
rine T cells were stably transfected with wild-type CD40 or
chimeric CD40/CD45. Flow cytometry con¢rmed normal bind-
ing properties of the mutant to CD40 ligand. Stimulation with
CD40 ligand resulted in clustering of wild-type CD40, while the
chimeric CD40/45 receptor failed to cluster. This correlated
with a de¢ciency of the chimeric receptor to activate JNK,
p38 MAP kinase and SAPK, known signaling molecules of
the intracellular pathway initiated by CD40. Forced crosslink-
ing of the CD40/45 chimeric receptor restored, at least partial-
ly, these signaling events. The results suggest that the trans-
membranous domain of CD40 is central for the recruitment to
and clustering of CD40 in membrane platforms.
; 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Receptor clustering has been shown for many receptor mol-
ecules and seems to be central in the generation of transmem-
branous signals. Receptors shown to aggregate upon stimula-
tion include the T cell receptor/CD3 complex [1,2], B cell
receptor [3,4], CD40 [5^8], FcO receptor 1 [9], CD95 [10,11],
CD28 [12], tumor necrosis factor receptor [13], platelet-de-
rived growth factor receptor [14], CD2, CD44, L-selectin or
integrins [15,16]. Many receptors cluster in distinct domains of
the cell membrane, termed lipid rafts or platforms. Lipid rafts
are microdomains in the plasma membrane that are enriched
in sphingolipids and cholesterol and separate from other
phospholipids in the cell membrane [17^19]. This separation
is mediated by a tight association of sphingolipids with each
other and with cholesterol, which seems to function as a
spacer between the bulky sphingolipids. Sphingolipid- and
cholesterol-enriched microdomains are resistant to solubiliza-
tion by non-ionic detergents at low temperatures [17,19], and,
thus, have also been named detergent-insensitive glycosphin-
golipid-enriched microdomains.
Disruption of rafts has been shown to prevent signaling by
many receptor molecules indicating a central function of lipid
rafts for signal transmission into the cell. However, the mo-
lecular determinants of receptor clustering are unknown.
Here, we employed the CD40 system to de¢ne some of the
molecular requirements for receptor clustering. CD40 has
been shown to be involved in a variety of immune responses,
for instance modulation of T lymphocyte activation, B lym-
phocyte di¡erentiation, immune regulation by dendritic cells,
germinal center formation, immunoglobulin isotype switching
and interleukin-12 production [20^24]. We and others have
recently demonstrated a recruitment and clustering of CD40
in sphingolipid-rich rafts of dendritic cells [5,6] and B lym-
phocytes [7,8]. Stimulation of CD40 appeared to trigger the
fusion of intracellular vesicles, which contain the acid sphin-
gomyelinase, with the cell membrane resulting in exposure of
the acid sphingomyelinase on the cell surface [8]. Activity of
the acid sphingomyelinase mediated the release of ceramide in
membrane microdomains and ceramide triggered the fusion of
small membrane rafts to large signaling platforms that
trapped CD40 [8]. CD40 trapping in ceramide-enriched plat-
forms resulted in the formation of large CD40 aggregates,
which were required for the initiation of CD40 signaling.
In contrast to CD40 and other receptor molecules that are
trapped in sphingolipid- and ceramide-enriched membrane
domains, the tyrosine phosphatase CD45 has been shown to
be excluded from lipid rafts [4,25,26]. The mechanisms of this
selective exclusion are unknown. Here, we employed this dif-
ference in membrane distribution to analyze molecular mech-
anisms of receptor^raft interactions and receptor clustering
and replaced the membrane spanning region of CD40 with
the transmembranous domain of the protein tyrosine phos-
phatase CD45. The data reveal that CD40 clustered in plat-
forms, while the CD40/45 chimera was excluded from lipid
rafts and platforms. Clustering of CD40 in membrane plat-
forms correlated with the activation of intracellular signaling
molecules and the failure of the CD40/CD45 chimera to clus-
ter resulted in a de¢ciency to initiate CD40 signaling.
2. Materials and methods
2.1. Cell culture and antibodies
T cell hybridoma 3A9 cells were from murine thymoma fused with
T cells. 3A9 T cell hybridoma and JY B lymphocytes were grown in
RPMI 1640 medium, COS cells were grown in Dulbecco’s modi¢ed
Eagle’s medium (DMEM). RPMI 1640 and DMEM were both sup-
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plemented with 10% fetal calf serum, 10 mM HEPES (pH 7.4), 2 mM
L-glutamine, 1 mM sodium pyruvate, 100 WM non-essential amino
acids, 100 U/ml penicillin, 100 Wg/ml streptomycin (all purchased
from Gibco BRL-Life Technologies, Grand Island, NY, USA) and
50 WM 2-mercaptoethanol.
Surface CD40 was stained with the mouse monoclonal anti-human
CD40 antibody 5C3 from Pharmingen (San Diego, CA, USA) or
recombinant Flag-tagged CD40 ligand from Alexis (San Diego, CA,
USA). Immunoprecipitation experiments and Western blots of CD40
were performed with a rabbit polyclonal anti-CD40 antibody (C-20)
from Santa Cruz (Santa Cruz, CA, USA), c-Jun amino-terminal ki-
nase (JNK-1) was detected with a rabbit polyclonal anti-JNK-1 anti-
body (C-17) from Santa Cruz. Recombinant, Flag-tagged CD40 li-
gand and enhancer were from Alexis. FITC-conjugated mouse anti-
Flag antibodies were from Upstate Biotechnology (Lake Placid, NY,
USA). Rabbit anti-phospho-p38, and anti-phospho-SAPK/JNK were
from New England Biolabs (Beverly, MA, USA).
2.2. Generation of chimeric receptor and transfectants
The transmembranous domains of CD40 and CD45 were deter-
mined according to the SwissProt database. The corresponding amino
acid sequence of CD40 is ALVVIPIIFGILFAILLVLVFI, that of
CD45 is ALIAFLAFLIIVTSIALLVVLY. CD40 and CD45 are
both type I membrane proteins and both transmembranous domains
contain 22 amino acids. The chimeric receptor of CD40 with the
transmembranous region of CD45 was generated by overlapping
PCR using extended primers. The extracellular domain was fused
with the transmembranous part of CD40 by ampli¢cation with the
5P primer GCT CTA GAA TGG TTC GTC TGC CTC TGC AG and
the 3P primer GTA GAG AAC AAC AAG CAG GGC TAT TGA
TGT CAC AAT AAT CAG AAA TGC CAG AAA TGC TAT CAG
TGC TCT CAG CCG ATC CTG GGG ACC ACA GAC AAC
ATC. The intracellular domain was fused to the transmembranous
domain using the 5P primer GCA CTG ATA GCA TTT CTG
GCA TTT CTG ATT ATT GTG ACA TCA ATA GCC CTG
CTT GTT GTT CTC TAC AAA AAG GTG GCC AAG AAG
CCA ACC AAT AAG GC and the 3P primer GTG CCC GGG
TCA CTG TCT CTC CTG CAC TGA GAT GC. These two over-
lapping fragments were then fused by PCR with the 5P primer GCT
CTA GAA TGG TTC GTC TGC CTC TGC AG containing a XbaI
site and the 3P primer GTG CCC GGG TCA CTG TCT CTC CTG
CAC TGA GAT GC containing a SmaI site. The resulting chimera
was subcloned into the expression vector pJK [27] using the XbaI and
SmaI sites and veri¢ed by sequencing. 3A9 cells were transfected by
electroporation with 40 Wg each of the CD40 expression plasmid pJK-
cd40, the chimeric receptor designated pJK-cd40/45 or the (empty)
control pJK plasmid. The pJK vector contains an elongation factor
promoter to induce constitutive protein expression. Stable transfec-
tants were selected using 3 mg/ml G418, transient transfections were
performed in COS cells using FuGENE 6 (Roche, Indianapolis, IN,
USA).
2.3. Receptor aggregation, £uorescence microscopy and £ow cytometry
(FACS)
1U106 3A9 cells per sample were centrifuged at 1200 rpm for 5 min,
resuspended in 50 Wl of pre-warmed RPMI 1640 and kept at 37‡C for
8 min. Cells were stimulated with 1 Wg/ml CD40 ligand plus 1 Wg/ml
enhancer to crosslink the Flag tag fused to the CD40 ligand. Stimu-
lation was stopped by addition of 1 ml ice-cold washing bu¡er (phos-
phate-bu¡ered saline supplemented with 2% fetal calf serum and 0.2%
sodium azide). Samples were then incubated at 4‡C for 45 min with
500 ng/ml of anti-CD40 antibody (Pharmingen), washed with ice-cold
washing bu¡er, stained with a cyanine 3.18 (Cy3)-coupled anti-mouse
Ig antibody and analyzed on a Zeiss (Axioplan 2) £uorescence micro-
scope. Receptor aggregates were de¢ned as an area of intense £uores-
cence on the cell surface, while unstimulated cells displayed a homo-
geneous distribution of £uorescence. In every sample at least 200 cells
were screened for the presence of aggregates and results are given as
percentage of cells positive for clusters at the indicated time. For
FACS analysis cells were stained as described above or with recombi-
nant Flag-tagged CD40 ligand coupled to a FITC anti-Flag antibody.
FACS analysis was performed on a Becton-Dickinson Calibur.
2.4. JNK activity
For detection of JNK activity, 4U106 cells were incubated for 20
min with CD40 ligand (1 Wg/ml) plus enhancer (1 Wg/ml) and lysed in
ice-cold lysis bu¡er containing 25 mM HEPES (pH 7.4), 0.1% SDS,
0.5% sodium deoxycholate, 1% Triton X-100, 125 mM NaCl, 10 mM
sodium £uoride, 10 mM Na3VO4, 10 mM sodium pyrophosphate, 10
mM EDTA, and 10 Wg/ml each of aprotinin and leupeptin as previ-
ously described [28]. Lysates were centrifuged at 21 000Ug for 10 min
at 4‡C, and JNK was immunoprecipitated from the supernatant at
4‡C for 4 h using polyclonal rabbit anti-mouse JNK. Immunocom-
plexes were immobilized on protein A/G agarose (Santa Cruz Inc.),
incubated for an additional 45 min at 4‡C, washed twice in lysis
bu¡er, twice in a bu¡er containing 132 mM NaCl, 20 mM HEPES,
5 mM KCl, 1 mM CaCl2, 0.7 mM MgCl2, 0.8 mM MgSO4, 1% NP40
and 2 mM Na3VO4, once in 100 mM Tris (pH 7.5), 100 mM LiCl,
and ¢nally twice in kinase reaction bu¡er consisting of 12.5 mM
morpholinopropanesulfonic acid (pH 7.5), 12.5 mM Q-glycerophos-
phate, 0.5 mM EGTA, 7.5 mM MgCl2, 0.5 mM NaF, 0.5 mM
Na3VO4. Immunoprecipitates were ¢nally resuspended in kinase re-
action bu¡er supplemented with 10 WCi/sample of [32P]QATP (6000 Ci/
mmol, Amersham, Freiburg, Germany), 10 WM ATP, and 1 Wg of
glutathione S-transferase (GST)-c-JUN (amino acids 1^79). The sam-
ples were incubated at 30‡C for 20 min, the kinase reaction was
stopped by addition of 5 Wl of boiling 5USDS sample bu¡er and
5% 2-mercaptoethanol. Proteins were separated by 10% SDS^
PAGE, electrophoretically transferred to nitrocellulose membranes
(Hybond) and analyzed by autoradiography. To test for equal
amounts of immunoprecipitated protein, the membranes were blocked
with bovine serum albumin after autoradiography, probed with anti-
JNK-1 antibodies, washed and developed using an alkaline phos-
phatase AP-coupled anti-rabbit antibody and the Tropix ECL sys-
tem.
The substrate GST-c-JUN was expressed in DH5K bacteria by in-
cubation with isopropyl-D-thiogalactopyranoside (200 WM) for 4 h.
Bacteria were lysed in a solution containing 25 mM HEPES (pH
7.4), 0.2% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 125
mM NaCl, and 10 Wg/ml each of aprotinin and leupeptin. The GST
fusion protein was puri¢ed by binding to glutathione Sepharose and
eluted in kinase reaction bu¡er supplemented with 20 mM gluta-
thione. The purity of the preparations was tested by SDS^PAGE
and Coomassie staining. Additional titration experiments revealed a
limit of JNK detection at approximately 0.5U105 cells/sample. The
substrate GST-c-JUN was added in large excess to achieve linear
assay kinetics.
2.5. Phosphorylation of p38K and SAPK/JNK
To determine serine/threonine phosphorylation of p38K [29^31]
0.5U106 3A9 cells per sample were washed, equilibrated at 37‡C for
8 min and stimulated by addition of CD40 ligand and enhancer. The
reaction was terminated by addition of 20 Wl ice-cold lysis bu¡er
consisting of 25 mM HEPES, pH 7.4, 0.1% SDS, 0.5% sodium deoxy-
cholate, 1% Triton X-100, 125 mM NaCl, 10 mM NaF, 10 mM
Na3VO4, 10 mM sodium pyrophosphate and 10 Wg/ml each of apro-
tinin and leupeptin. Cell lysates were centrifuged and the supernatants
were added to 5USDS sample bu¡er and 5% 2-mercaptoethanol.
Proteins were separated by 10% SDS^PAGE and the blots were
probed with the monoclonal anti-phospho-p38K antibody 28B10
(Cell Signaling Technology, Beverly, MA, USA) following the instruc-
tions of the vendor. The anti-phospho-p38K antibody speci¢cally de-
tects phospho-Thr180 and phospho-Tyr182 for p38 kinase.
3. Results
3.1. CD40/45 mutants bind CD40 ligand
In order to identify mechanisms that determine the presence
of receptor molecules in lipid rafts, we replaced the transmem-
branous domain of CD40, known to be present in ceramide-
enriched platforms [8], with that of CD45, known to be ex-
cluded from rafts [24^26].
Murine T cell 3A9 hybridoma or COS cells were transfected
with wild-type CD40, the CD40/45 chimeric receptor or the
empty pJK vector that served as control. Flow cytometry
analysis revealed a similar surface expression of CD40 and
CD40/45 in 3A9 cells (Fig. 1A) or COS cells (not shown).
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The expression levels of both molecules were similar to that of
CD40 in JY lymphoblastoid B cells (Fig. 1A), which are
known to endogenously express CD40 and served as a con-
trol.
In addition, the CD40 and the CD40/45 transfectants
showed similar a⁄nity to CD40 ligand as determined by
FACS analysis upon staining of the cells with a FITC-coupled
CD40 ligand (Fig. 1B). This indicates that the switch of the
transmembranous domain did not signi¢cantly alter the ligand
binding capacity of the extracellular domain of CD40.
3.2. CD40/45 mutants fail to cluster upon stimulation
We employed these transfectants to analyze receptor local-
ization and clustering in sphingolipid-enriched domains. We
have recently shown that stimulation via CD40 alters rafts by
acid sphingomyelinase-mediated release of ceramide in those
rafts [8,10]. Ceramide triggered the fusion of rafts to large
membrane platforms and, second, served to trap CD40 mol-
ecules in those platforms ¢nally resulting in a clustering of
CD40 [8]. To test whether the transmembranous domain of
CD40 is involved in clustering of the receptor in raft-derived
Fig. 1. Transfection of CD40 and CD40/CD45 chimeric constructs. A: Transfection of wild-type CD40 or the CD40/CD45 chimeric construct
results in surface expression of both proteins. Surface expression of the receptor molecules was determined by £ow cytometry upon staining of
the cells with FITC-labeled anti-CD40 antibodies. The ¢lled curve represents 3A9 cells transfected with empty control vector, the red line
CD40 transfected cells, the black line 3A9 hybridoma transfected with chimeric CD40/45 and the dotted line is a control staining of JY cells
known to endogenously express CD40. B: Wild-type CD40 and the mutant CD40/45 construct exhibit similar binding capacities to CD40 li-
gand. Cells were incubated with FITC-coupled anti-Flag antibodies and binding of the ligand was determined by £ow cytometry. The ¢lled
curve represents binding to 3A9 cells transfected with empty vector, the red line binding to CD40 transfected cells, the black line binding to
3A9 hybridoma transfected with chimeric CD40/45. The data in A and B are representative of three £ow cytometry studies each with very sim-
ilar results.
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membrane platforms, we treated 3A9 cells expressing CD40 or
CD40/45 chimera with recombinant CD40 ligand and mea-
sured clustering of the receptor by £uorescence microscopy.
The data revealed that wild-type CD40 clustered within min-
utes after stimulation, while the chimeric CD40/45 molecule
failed to cluster (Fig. 2). These data identify the transmem-
branous domain of CD40 as an important element for clus-
tering of the receptor upon stimulation.
Fig. 2. CD40, but not the CD45/45 protein, clusters upon stimulation. A: Stimulation of 3A9 cells expressing CD40 results in rapid clustering
of CD40, while the cells expressing CD40/45 fail to form receptor cluster upon stimulation. Clustering was analyzed by £uorescence microsco-
py. Shown is a typical result of three independent studies. B: The quantitative analysis of CD40 and CD40/45 clustering after stimulation with
CD40 ligand indicates a failure of the CD40/45 mutant to cluster. Data (meanUS.D.) were obtained from three independent experiments. The
quanti¢cation of clustering was con¢rmed by a second independent observer. These independent studies revealed a variation of less than 5% in
the determination of receptor clustering.
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3.3. The clustering de¢ciency of CD40/45 mutants correlates
with a signaling defect
Previous data suggested that disruption of rafts prevents
cellular activation via CD40 [8]. We, therefore, tested whether
the failure of the CD40/45 mutant to cluster correlates with a
defect in the initiation of intracellular signals elicited by
CD40. To this end we determined the phosphorylation and
activation of p38 MAP kinase, SAPK and JNK, known tar-
gets of CD40 [32^35], in 3A9 T cells transfected with wild-
type CD40 or the CD40/45 chimera. Furthermore, we ana-
lyzed whether CD40-mediated activation of intracellular sig-
naling molecules requires the presence of the receptor in lipid
domains or whether a clustering of the receptor is already
su⁄cient to initiate at least some signaling. In the latter
case, an arti¢cial clustering of chimeric CD40/45 molecules
should permit the activation of the cells. The results revealed
that cells expressing the chimeric CD40/45 receptor failed to
stimulate JNK or to phosphorylate p38K upon treatment with
CD40 ligand (Fig. 3A,B). Quantitative analysis of the blots by
laser scanning densitometry revealed a 5U 0.45-fold increase
of JNK activity after stimulation of CD40-expressing cells
(meanUS.D., n=2), while the activity of JNK after stimula-
tion of CD40/CD45-transfected cells was unaltered (1.0 U
0.15-fold change). The phosphorylation of p38K increased
12U 2-fold in CD40-positive cells, but only 1.2 U 0.5-fold in
the CD40/45-transfected cells (meanUS.D., n=4) after stim-
ulation of the cells with 0.5 Wg/ml CD40 ligand plus 1 Wg/ml
enhancer. Forced crosslinking of the CD40/45 mutant using
higher concentrations of crosslinked CD40 ligand, i.e. up to
5 Wg/ml CD40 ligand and 2 Wg/ml enhancer, at least partially
restored phosphorylation of p38K (Fig. 3C). Laser scanning
densitometry revealed that stimulation with doses between
1 and 5 Wg/ml CD40 ligand and 2 Wg/ml enhancer triggered
a 12.5 U 3-fold and a 6U 1-fold increase of p38K phosphory-
lation in CD40-positive cells or CD40/45-expressing cells, re-
spectively (meanUS.D., n=3). This indicates that the muta-
tion did not abolish the ability of the receptor to transmit
signals into the cell.
4. Discussion
Although many receptors have been shown to cluster in
detergent-resistant membrane domains, molecular mecha-
nisms mediating the preferential partitioning of receptors in
those domains require de¢nition. The present data identify the
transmembranous domain of CD40 as an important element
of the receptor to interact with sphingolipid-enriched rafts and
to cluster in membrane platforms upon stimulation. The fail-
ure of the CD40/45 mutant to cluster is not caused by a
simple conformational change or inactivity of the mutant pro-
tein, since forced crosslinking of the CD40/45 molecule is
su⁄cient to trigger phosphorylation of p38K. Further, the
transmembranous domains of CD40 and CD45 are both com-
posed of 22 amino acids (CD40: ALVVIPIIFGILFAILLVL-
VFI and CD45: ALIAFLAFLIIVTSIALLVVLY) excluding a
large di¡erence in the length of the transmembranous domain
as the cause of the inability of the CD40/45 mutant to cluster.
A simple model might suggest that individual amino acid
residues mediate the di¡erent abilities of the receptor mole-
cules to cluster within lipid rafts. The transmembranous do-
main of CD40 contains only uncharged amino acids and three
phenylalanine residues, which might facilitate integration of
the receptor in hydrophobic, sphingolipid- and cholesterol-
enriched membrane platforms. In contrast, the transmembra-
nous domain of CD45 contains central threonine and serine
residues with aliphatic hydroxyl side chains and a tyrosine
residue at the interface to the cytosol. The hydrophilic amino
acids may render the transmembranous domain of CD45 less
hydrophobic and prevent integration into ceramide-enriched
lipid platforms. However, this models fails to explain a selec-
tive recruitment of activated, CD40 ligand-bound CD40 mol-
ecules into lipid rafts. Therefore, we would like to suggest that
the release of ceramide in rafts not only triggers fusion of
those rafts to larger platforms [36], and alters the hydropho-
bicity of the membrane domain, but may also alter the diam-
eter of the cell membrane in the platform area. Binding of the
Fig. 3. Activation of JNK and p38K depends on receptor clustering.
A: Stimulation of 3A9 cells expressing wild-type CD40 results in ac-
tivation of JNK, while cells expressing the chimeric CD40/45 mu-
tant failed to respond. Cells were stimulated for the indicated time
with 1 Wg/ml CD40 ligand and 1 Wg/ml anti-Flag antibodies ( = en-
hancer). The activity of JNK was determined by phosphorylation of
the substrate GST-Jun. The autoradiography is representative of
two experiments. B: Cells expressing CD40 ligand already respond
to 0.1 Wg/ml CD40 ligand plus 1 Wg/ml enhancer with phosphory-
lation of p38K. Cells expressing the chimeric mutant fail to phos-
phorylate p38K at low doses of crosslinked CD40 ligand. Higher
doses of CD40 ligand induce a limited phosphorylation of p38K in
these cells. Cells were stimulated with the indicated dose of CD40 li-
gand crosslinked with 1 Wg/ml enhancer. Phosphorylation of p38K
was determined by Western blotting using phospho-speci¢c anti-
p38K antibodies. The studies were repeated four times with very
similar results. C: Arti¢cial crosslinking of CD40 using doses as
high as 5 Wg/ml of the CD40 ligand and 2 Wg/ml of the enhancer re-
stores, at least partially, phosphorylation of p38K. Soluble CD40 li-
gand without addition of enhancer is insu⁄cient to initiate CD40
signaling. Phosphorylation of p38K was determined by Western
blotting using phospho-speci¢c anti-p38K antibodies. The data are
representative of three experiments.
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ligand to CD40 may change the conformation of the receptor
to ¢t into a ceramide-enriched membrane domain, while the
presence in membrane parts with other diameters might be
energetically unfavorable for the ligand^receptor complex.
Vice versa, the transmembranous domain of CD45 might fa-
vorably ¢t into the cell membrane outside rafts, while its
presence in ceramide-enriched platforms with other diameters
might be energetically unlikely.
Our results demonstrate that rapid CD40 clustering de-
pends on association with rafts and exclusion from these mi-
crodomains results in the inability to cluster and to signal
upon stimulation. Forced crosslinking of the CD40/45 mutant
at least partially restored signaling indicating that the cluster-
ing event per se is central for transmission of a signal via
CD40 into the cell. This suggests that physiological clustering
of CD40 in membrane platforms serves to initiate a high
local concentration of receptor molecules that may permit
the transactivation of molecules associated with CD40, e.g.
JAK3 [37]. However, additional functions of CD40 clustering
in membrane platforms that appear to contribute to full acti-
vation via CD40 might be a close contact of the receptor with
signaling molecules present in lipid platforms, an exclusion of
inhibitory signaling molecules, e.g. CD45, and/or a direct
modi¢cation of CD40 signaling by ceramide. In a physiolog-
ical situation, the presence of CD40 in ceramide-enriched
membrane platforms might also limit lateral di¡usion and
promote binding to its ligand.
In conclusion, the present study indicates that the trans-
membranous domain of CD40 plays a central role for cluster-
ing of the receptor in membrane platforms that is required for
e⁄cient signaling of CD40.
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